VEGFA and glioblastoma: Although bevacizumab attributes to regional hypoxia in recurrent GBM patients, the addition of anti-VEGF antibody bevacizumab to carmustine would not enhance incidence of hematologic toxicity, validating the safety of this combinatory therapy in treating GBM patients [132].